The trademark application CASVIVIP was filed by AstraZeneca AB, a corporation established under the laws of the Kingdom of Sweden (the "Applicant"). The application was published for oppositions on June 22, 2022, and it was registered by office on September 29, 2022 without any oppositions.
The application was filed in English (German was selected as the second language).